Phospholipid drug analogs

A method for ameliorating bladder cancer in a subject, wherein the bladder cancer is selected from the group consisting of superficial bladder cancer, transitional cell carcinoma, squamous cell cancer, adenocarcinoma and carcinosarcoma, comprising:

• administering to the subject in need thereof a compound of formula A in an amount effective to treat the bladder cancer, the compound of formula A having the structure:
• or a pharmaceutically acceptable salt, tautomer or hydrate thereof, wherein:
• X1 is —O—, —S—, or —NRa—;
• Ra is hydrogen, C1-C10 alkyl, or substituted C1-C10 alkyl, or Ra and R1 taken together with the nitrogen atom can form a heterocyclic ring or a substituted heterocyclic ring, wherein the substituents on the alkyl or heterocyclic groups are hydroxy, C1-C10 alkyl, hydroxyl C2-C10 alkenyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C1-C6 alkoxy C1-C6 alkylene, amino, cyano, halogen or aryl;
• R1 is hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl, C1-C10 alkoxy, substituted C1-C10 alkoxy, C3-C9 cycloalkyl, substituted C3-C9 cycloalkyl, C5-C10 aryl, substituted C5-C10 aryl, C5-C9 heterocyclic, substituted C5-C9 heterocyclic, C1-C6 alkanoyl, substituted C1-C6 alkanoyl, C1-C6 heteroalkyl, C1-C6 alkoxycarbonyl, or substituted C1-C6 alkoxycarbonyl, wherein the substituents on the alkyl, cycloalkyl, alkanoyl, alkoxycarbonyl, aryl, heterocyclic groups are hydroxyl, C1-C10 alkyl, hydroxyl C1-C10 alkylene, C1-C6 alkoxy, C3-C9 cycloalkyl, C5-C9 heterocyclic, C1-6 alkoxy C2-8 alkenyl, amino, cyano, halogen or aryl;
• each R2 independently is hydrogen, —OH, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxy, substituted C1-C6 alkoxy, —C(O)— C1-C6 alkyl (alkanoyl), substituted —C(O)— C1-C6 alkyl, —C(O)— C6-C10 aryl (aroyl), substituted —C(O)— C6-C10 aryl, —C(O)OH (carboxyl), —C(O)O— C1-C6 alkyl (alkoxycarbonyl), substituted —C(O)O— C1-C6 alkyl, —NRaRb, —C(O)NRbRc (carbamoyl), substituted C(O)NRbRc, C5-C9 cyclic, substituted C5-C9 cyclic, C5-C9 heterocyclic, substituted C5-C9 heterocyclic, halo, nitro, or cyano, wherein the substituents on the alkyl, cyclic, aryl or heterocyclic groups are hydroxy, C1-C10 alkyl, hydroxyl C1-C10 alkylene, C1-C6 alkoxy, C3-C6 cycloalkyl, C1-C6 alkoxy C1-C6 alkylene, amino, cyano, halogen or aryl;
• each Rb and Rc independently is hydrogen, C1-C10 alkyl, substituted C1-C10 alkyl, C1-C10 alkoxy, substituted C1-C10 alkoxy, C3-C9 cycloalkyl, substituted C3-C9 cycloalkyl, C5-C10 aryl, substituted C5-C10 aryl, C5-C9 heterocyclic, substituted C5-C9 heterocyclic, C1-C6 alkanoyl, substituted C1-C6 alkanoyl, C1-C6 heteroalkyl, C1-C6 alkoxycarbonyl, or substituted C1-C6 alkoxycarbonyl, wherein the substituents on the alkyl, cycloalkyl, alkanoyl, alkoxycarbonyl, aryl or heterocyclic groups are hydroxyl, C1-C10 alkyl, hydroxyl C1-C10 alkylene, C1-C6 alkoxy, C3-C9 cycloalkyl, C5-C9 heterocyclic, C1-6 alkoxy C2-8 alkenyl, amino, cyano, halogen or aryl;
• X2 is a bond or a linker;
• n is 0, 1, 2, 3 or 4;
• X3 is a bond or a —PO4—;
• R3 is a C1-C6 alkyl substituted with —OC(O)—Rd and —OC(O)—Re;
• C1-C6 alkyl substituted with —OC(O)—Rd, —OC(O)—Re, and one or more further substituents;
• C2-8 alkenyl substituted with —OC(O)—Rd and —OC(O)—Re;
• or C2-8 alkenyl substituted with —OC(O)—Rd, —OC(O)—Re, and one or more further substituents;
• wherein the one or more further substituents independently are hydroxyl, C1-C10 alkyl, hydroxyl C1-C10 alkylene, C1-C6 alkoxy, C3-C9 cycloalkyl, C5-C9 heterocyclic, C1-6 alkoxy C1-6 alkylene, amino, cyano, halogen or aryl;
• and
• —OC(O)—Rd and —OC(O)—Re are —OC(O)—(CH2)10—CH3 or —OC(O)—(CH2)12—CH3.